Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Arbutus Biopharma Corporation

< Previous 1 2 Next >
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS ROIV
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Provides 2025 Corporate and Financial Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Present at Jefferies London Healthcare Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Participate in Two Upcoming Investor Conferences
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Participate in Jefferies Global Healthcare Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Present Imdusiran Data at EASL Congress 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Participate in Two Upcoming Investor Conferences
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Participate in Two Upcoming Investor Conferences
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.